Interleukin‐6 Inhibitor, Tocolizumab, for COVID‐19: evidence review of the clinical benefit and harm
Date
2020-04-15Metadata
Show full item recordThe following license files are associated with this item:
Except where otherwise noted, this item's license is described as Attribution 3.0 United States